2.3 Longevity clinics
These new clinics focus on proactive, preventative care for aging. These clinics go beyond traditional medicine’s reactive approach to preventing disease using advanced diagnostic tools like genetic testing, metabolic analysis, and cellular-level assessments to identify biological aging markers and develop personalized plans for diet, exercise, supplements, and lifestyle changes to slow or even reverse biological aging. Based on these assessments, they offer tailored interventions ranging from personalized nutrition and exercise plans to hormonal balance therapies, targeted supplements, and in some cases, novel therapies like senolytics or stem cell therapy.
While the foundational principles of a healthy diet, regular exercise, and stress management are well-established and evidence-based, many of the newer, more experimental treatments are still in the early stages of clinical validation, creating a mixed bag of scientifically-backed services and cutting-edge interventions with a nascent evidence-base in human trials, or w ith only animal-based research backing.
The evidence base for these treatments is a critical consideration for future investment and progress in this space. Lifestyle interventions like diet, exercise, and sleep optimization have an undeniable and well-documented impact on health and longevity (Stanger, 2025). The data on more advanced interventions is more varied. Senolytics and Regenerative Medicine are cutting-edge treatments that directly target the cellular processes of aging. Senolytics are a class of drugs that selectively remove senescent (“zombie”) cells, which have shown promise in animal studies for extending healthspan but lack extensive human clinical trial data (DVC Stem, 2025). Other treatments, such as Metformin, a diabetes drug, and Rapamycin, an immunosuppressant, have shown longevity benefits in animal models and are being explored in human trials, but their use for healthy individuals is still considered off-label. Regenerative medicine and cellular reprogramming aim to repair or replace damaged tissues and organs to restore yo
Interventions commonly offered in longevity clinics are covered in more detail in the Innovation in Prevention chapter, and the table below outlines common treatments, their purported actions, and the current level of evidence supporting them.
|
Intervention |
Action on Health Outcomes | Level of Evidence Base |
|
Comprehensive Diagnostics (Epigenetic clocks, advanced blood panels, full-body scans) |
Measures “biological age” and identifies early risk factors for chronic disease (e.g., inflammation, metabolic dysfunction) to inform personalized interventions. |
Strong evidence. Epigenetic clocks (like Horvath’s) are well-validated for predicting biological age and mortality risk (Lu et al., 2025; NHGRI, 2025). |
|
Personalized Nutrition & Exercise |
Optimizes metabolism, reduces inflammation, improves cardiovascular health, and maintains muscle mass, all of which are critical for preventing age-related decline. |
Very strong evidence. These are foundational, scientifically-backed interventions for improving healthspan and reducing chronic disease risk. (AHA, 2025; Stanger, 2025). |
| Metformin |
A diabetes drug used off-label to improve metabolic health, reduce inflammation, and activate cellular pathways associated with longevity. |
Moderate evidence in humans. It has shown significant anti-aging effects in animal models and is currently being studied in human trials (TAME trial) for its longevity benefits. (PMC, 2025; Stanger, 2025). |
| NAD+ IV Therapy | Aims to boost levels of Nicotinamide adenine dinucleotide (NAD+), a molecule crucial for cellular energy and DNA repair. |
Low evidence in humans. While animal studies show promise, human clinical trials are limited and mostly focus on precursors like NR or NMN, with mixed results on direct anti-aging outcomes. (Aimee Victoria Long, 2025). |
| Senolytics |
A class of drugs that selectively remove “senescent” or “zombie” cells that accumulate with age and contribute to inflammation and tissue dysfunction. |
Low evidence in humans. Promising results in animal models and early human trials for specific diseases (e.g., idiopathic pulmonary fibrosis), but widespread use for general anti-aging is still experimental. (DVC Stem, 2025; NATAP, 2025). |
| Peptide Therapies | Uses specific peptide molecules (short chains of amino acids) to signal for various biological processes like tissue repair, hormone regulation, and collagen production. |
Mixed evidence. Some peptides, like collagen peptides, have moderate evidence for skin and bone health. Others are highly speculative and lack significant human trial data. (Medical News Today, 2025). |
|
Stem Cell Therapy |
Uses stem cells to promote tissue repair, reduce systemic inflammation, and restore organ function. |
Low evidence. There is a lack of large-scale, placebo-controlled human trials for general anti-aging. Evidence for specific conditions (e.g., frailty) is emerging, but much of the field remains unregulated and unproven. (Cellmedicine, 2025). |
Table: Longevity Clinic Interventions
The healthy aging field requires a concerted effort from both policymakers and the private sector to scale responsibly. For policymakers, this means establishing a clear regulatory framework for novel longevity interventions, akin to the approval pathways for new drugs and medical devices. This is crucial for protecting consumers from unproven or potentially harmful treatments while creating a clear path for private companies to innovate and bring evidence-based products to market.
Public policy can also play a vital role in consumer education and awareness, helping the public understand the difference between scientifically validated health practices and unproven therapies.
Additionally, integrating longevity medicine, or geroscience, into mainstream medical training is essential. Medical schools and professional bodies need to develop curricula and certifications that equip doctors with the knowledge to interpret advanced diagnostics and provide evidence-based longevity care, shifting the focus from disease treatment to health optimization.
The private sector has to date been the major driver of this change. Investors should prioritize ventures that not only have a strong business model but also a robust scientific foundation and a commitment to clinical validation. This means funding companies that are conducting human trials, partnering with academic institutions, and contributing to the body of scientific knowledge. Private companies can also help by establishing industry-wide best practices and self-regulatory bodies to ensure ethical standards and transparency.
By investing in scalable solutions, investors can help make longevity-focused care more accessible to a broader population, not just the ultra-wealthy. This collaborative approach between the public and private sectors is necessary to build a sustainable and credible healthy aging industry that truly delivers on its promise of extending healthspan for all.